InterMune Inc. (Nasdaq: ITMN) reported positive results from a Phase 3 ASCEND trial of its idiopathic pulmonary fibrosis treatment pirfenidone. The stock price more than doubled by leaping $23.55 to $37.51.
InterMune Reports Positive Results
February 25, 2014 at 14:01 PM EST
